Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar
This article was originally published in PharmAsia News
Celltrion takes a step forward in its biosimilar ambitions by commencing clinical trials of a key pipeline product.
You may also be interested in...
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
SEOUL - South Korea's biosimilar front-runner Celltrion Inc. continued its upward swing in the first quarter of 2011with first quarter sales and net profit reaching record highs